The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative detection methods for organomercurial biosynthesis in microbial communities.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel shipping container designed to protect live cell cultures during transport.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of advanced gene editing technology for therapeutic applications.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV gene therapy for Leber Congenital Amaurosis caused by CEP290 mutations.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon-gamma as a therapeutic agent for proliferative eye diseases.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon gamma as a therapeutic agent to restore retinal fluid absorption.